{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T21:50:58Z","timestamp":1794088258604,"version":"4.8.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012830","name":"Hunan Province Development and Reform Commission","doi-asserted-by":"publisher","award":["2021-212"],"award-info":[{"award-number":["2021-212"]}],"id":[{"id":"10.13039\/100012830","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017695","name":"Health Commission of Hunan Province","doi-asserted-by":"publisher","award":["2100499"],"award-info":[{"award-number":["2100499"]}],"id":[{"id":"10.13039\/100017695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023JJ30906"],"award-info":[{"award-number":["2023JJ30906"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2022JJ40792"],"award-info":[{"award-number":["2022JJ40792"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170041"],"award-info":[{"award-number":["82170041"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100099"],"award-info":[{"award-number":["82100099"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jinf.2024.106190","type":"journal-article","created":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T01:25:13Z","timestamp":1717291513000},"page":"106190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"89","author":[{"given":"Juan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0580-2515","authenticated-orcid":false,"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jinf.2024.106190_bib1","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/S1473-3099(21)00703-9","article-title":"WHO clinical case definition working group on post-COVID-19 condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus","volume":"22","author":"Soriano","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"10302","key":"10.1016\/j.jinf.2024.106190_bib2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(21)01755-4","article-title":"1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study","volume":"398","author":"Huang","year":"2021","journal-title":"Lancet Lond Engl"},{"issue":"8","key":"10.1016\/j.jinf.2024.106190_bib3","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(23)00239-4","article-title":"Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations","volume":"11","author":"Parotto","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.jinf.2024.106190_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2213-2600(23)00387-9","article-title":"3-year outcomes of discharged survivors of COVID-19 following the SARS-CoV-2 omicron (B.1.1.529) wave in 2022 in China: a longitudinal cohort study","volume":"12","author":"Zhang","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.jinf.2024.106190_bib5","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S2213-2600(23)00238-2","article-title":"Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness","volume":"11","author":"Pandharipande","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jinf.2024.106190_bib6","first-page":"p2622","article-title":"Update to living WHO guideline on drugs for COVID-19","volume":"383","author":"Group BMJP","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2024.106190_bib7","doi-asserted-by":"crossref","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for COVID-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jinf.2024.106190_bib8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jinf.2023.01.014","article-title":"The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: a retrospective cohort study including 91,528 patients","volume":"86","author":"Liu","year":"2023","journal-title":"J Infect"},{"issue":"7","key":"10.1016\/j.jinf.2024.106190_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28951","article-title":"The effect of nirmatrelvir-ritonavir on the long-term risk of neuropsychiatric sequelae following COVID-19","volume":"95","author":"Liu","year":"2023","journal-title":"J Med Virol"},{"issue":"8","key":"10.1016\/j.jinf.2024.106190_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28992","article-title":"Effectiveness of oral antiviral agents on long-term cardiovascular risk in nonhospitalized patients with COVID-19: a multicenter matched cohort study","volume":"95","author":"Liu","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.jinf.2024.106190_bib11","article-title":"Incidence of symptoms associated with post-acute sequelae of SARS-CoV-2 infectionin non-hospitalized vaccinated patients receiving nirmatrelvir-ritonavir","author":"Patel","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.jinf.2024.106190_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074572","article-title":"Molnupiravir and risk of post-acute sequelae of COVID-19: cohort study","author":"Xie","year":"2023","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jinf.2024.106190_bib13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","article-title":"Association of treatment with nirmatrelvir and the risk of post\u2013COVID-19 condition","volume":"183","author":"Xie","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.jinf.2024.106190_bib14","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s15010-023-02028-5","article-title":"The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study","volume":"51","author":"Bertuccio","year":"2023","journal-title":"Infection"},{"issue":"8","key":"10.1016\/j.jinf.2024.106190_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29014","article-title":"Paxlovid reduces the risk of Long COVID in patients six months after hospital discharge","volume":"95","author":"Wang","year":"2023","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.jinf.2024.106190_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28750","article-title":"Efficacy of nirmatrelvir and ritonavir for post-acute COVID-19 sequelae beyond 3 months of SARS-CoV-2 infection","volume":"95","author":"Chuang","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.jinf.2024.106190_bib17","article-title":"Association of nirmatrelvir\/ritonavir treatment with long COVID symptoms in an online cohort of non-hospitalized individuals experiencing breakthrough SARS-CoV-2 infection in the Omicron Era. preprint","author":"Durstenfeld","year":"2023","journal-title":"Infect Dis (except\u00a0HIV\/AIDS)"},{"issue":"11","key":"10.1016\/j.jinf.2024.106190_bib18","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.7326\/M23-1394","article-title":"Effectiveness of nirmatrelvir-ritonavir against the development of Post-COVID-19 conditions among U.S. Veterans: a target trial emulation","volume":"176","author":"Ioannou","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jinf.2024.106190_bib19","article-title":"Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes","author":"Bajema","year":"2022","journal-title":"medRxiv"},{"issue":"23","key":"10.1016\/j.jinf.2024.106190_bib20","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.3390\/jcm12237375","article-title":"Effectiveness of antiviral therapy on long COVID: a systematic review and meta-analysis","volume":"12","author":"Choi","year":"2023","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.jinf.2024.106190_bib21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"10350","key":"10.1016\/j.jinf.2024.106190_bib22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(22)01214-4","article-title":"Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study","volume":"400","author":"Ballering","year":"2022","journal-title":"Lancet Lond Engl"},{"issue":"21","key":"10.1016\/j.jinf.2024.106190_bib23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.15585\/mmwr.mm7121e1","article-title":"Post\u2013COVID conditions among adult COVID-19 survivors aged 18\u201364 and \u226565 years \u2014 United States, March 2020\u2013November 2021","volume":"71","author":"Bull-Otterson","year":"2022","journal-title":"Morb Mortal Wkly Rep"},{"issue":"9","key":"10.1016\/j.jinf.2024.106190_bib24","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(22)00126-6","article-title":"Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study","volume":"10","author":"Huang","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jinf.2024.106190_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bbi.2021.12.020","article-title":"Fatigue and cognitive impairment in Post-COVID-19 Syndrome: a systematic review and meta-analysis","volume":"101","author":"Ceban","year":"2022","journal-title":"Brain Behav Immun"},{"issue":"3","key":"10.1016\/j.jinf.2024.106190_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: major findings, mechanisms and recommendations","volume":"21","author":"Davis","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jinf.2024.106190_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.698169","article-title":"Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms","volume":"12","author":"Proal","year":"2021","journal-title":"Front Microbiol"},{"issue":"6585","key":"10.1016\/j.jinf.2024.106190_bib28","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1126\/science.abm8108","article-title":"The immunology and immunopathology of COVID-19","volume":"375","author":"Merad","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jinf.2024.106190_bib29","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.86015","article-title":"RECOVER mechanistic pathways task force. Viral persistence, reactivation, and mechanisms of long COVID","volume":"12","author":"Chen","year":"2023","journal-title":"eLife"},{"issue":"6","key":"10.1016\/j.jinf.2024.106190_bib30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamainternmed.2023.0750","article-title":"Risk factors associated with post\u2212COVID-19 condition: a systematic review and meta-analysis","volume":"183","author":"Tsampasian","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.jinf.2024.106190_bib31","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jinf.2023.02.029","article-title":"Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase","volume":"86","author":"Wan","year":"2023","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.jinf.2024.106190_bib32","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/j.jinf.2023.02.007","article-title":"Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors","volume":"86","author":"Hsu","year":"2023","journal-title":"J Infect"},{"issue":"15","key":"10.1016\/j.jinf.2024.106190_bib33","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jinf.2024.106190_bib34","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1056\/NEJMe2402224","article-title":"Treating acute COVID-19 - final chapters still unwritten","volume":"390","author":"Gandhi","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jinf.2024.106190_bib35","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJMoa2309003","article-title":"Nirmatrelvir for vaccinated or unvaccinated adult outpatients with COVID-19","volume":"390","author":"Hammond","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jinf.2024.106190_bib36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17425255.2024.2339397","article-title":"Adverse events related to drug-drug interactions in COVID-19 patients. A persistent concern in the post-pandemic era: a systematic review","volume":"20","author":"Conti","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jinf.2024.106190_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104851","article-title":"Probing long COVID through a proteomic lens: a comprehensive two-year longitudinal cohort study of hospitalised survivors","volume":"98","author":"Gu","year":"2023","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.jinf.2024.106190_bib38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/ehjcvp\/pvad025","article-title":"Vascular mechanisms of post-COVID-19 conditions: Rho-kinase is a novel target for therapy","volume":"9","author":"Sykes","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharm"},{"issue":"170","key":"10.1016\/j.jinf.2024.106190_bib39","article-title":"Balancing the value and risk of exercise-based therapy post-COVID-19: a narrative review","volume":"32","author":"Singh","year":"2023","journal-title":"Eur Respir Rev J Eur Respir Soc"},{"key":"10.1016\/j.jinf.2024.106190_bib40","doi-asserted-by":"crossref","unstructured":"Li C, Qian W, Wei X, Narasimhan H, Wu Y, Arish M, et al. Comparative single-cell analysis reveals IFN-\u03b3 as a driver of respiratory sequelae post COVID-1. 2023; doi: 10.1101\/2023.10.03.560739.","DOI":"10.1101\/2023.10.03.560739"},{"key":"10.1016\/j.jinf.2024.106190_bib41","unstructured":"Stanford University. Selective trial of paxlovid for PASC (STOP-PASC): randomized double-blind placebo-controlled pilot trial of paxlovid for the treatment of PASC. Clinical Trial Registration. clinicaltrials.gov; 2023."},{"key":"10.1016\/j.jinf.2024.106190_bib42","unstructured":"Krumholz HM. An interventional decentralized phase 2, randomized, double-blind, 2-arm study to investigate the efficacy and safety of orally administered nirmatrelvir\/ritonavir compared with placebo\/ritonavir in participants with long COVID. Clinical Trial Registration. clinicaltrials.gov; 2024."},{"key":"10.1016\/j.jinf.2024.106190_bib43","unstructured":"Anonymous. RECOVER-VITAL: platform protocol to measure the effects of antiviral therapies on long COVID symptoms - full text view - ClinicalTrials.Gov. n.d. Available from: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05595369\u3009 [Last accessed: 5\/21\/2024]."}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324001245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324001245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T03:38:25Z","timestamp":1763177905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445324001245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0163445324001245"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106190","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106190"}}